Radius is a biopharmaceutical company focused on developing therapeutics for the treatment of osteoporosis and other women’s health conditions. We aspire to improve the quality of life in older adults by treating age-related conditions.
Radius is committed to the development of new therapeutics for the large and underserved osteoporosis market. The Company’s lead product candidate, BA058, is in development, in both injection (BA058-SC) and transdermal (BA058-TD) methods of administration, to reduce the risk of complications associated with osteoporosis, such as fracture. In Phase 2 trials, BA058-SC has produced faster and greater bone mineral density increases at the spine and the hip.